Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
|Articles|December 29, 2017
Supplements and Featured Publications
- Pseudobulbar Affect: Considerations for Managed Care Professionals
- Volume 23
- Issue 18
Posttest
Advertisement
Release date:
November 20, 2017
Expiration date:
November 20, 2018
Physician Credit
Instructions for Receiving Continuing Pharmacy Education (CPE) Credit: Testing and Grading Information
This lesson is free online. Receive instant grading and request your CE credit at www.PharmacyTimes.org.
Testing and Grading Directions
- Each participant evaluating the activity and achieving a passing grade of 70% or higher on the online posttest is eligible to receive CE credit.
- Participants receiving a failing grade on the exam will be notified and permitted to take 1 reexamination at no cost.
- To receive your credit online, go to www.PharmacyTimes.org and complete the online posttest (achieving a passing grade of 70% or better) and the online activity evaluation form before the expiration date. Your CE credit will be automatically uploaded to CPE Monitor™. Please ensure your Pharmacy Times® account is updated with your NABP e-profile ID number and your date of birth (MMDD format). Participation data will not be uploaded into CPE Monitor™ if you do not have your NABP e-profile ID number and date of birth entered into your profile on www.PharmacyTimes.org.
Articles in this issue
almost 9 years ago
Pharmacotherapeutic Management of Pseudobulbar Affectalmost 9 years ago
Participating FacultyAdvertisement
Related to this article
AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote monitoring policies.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
A higher ratio of red blood cell distribution width to albumin was tied to greater all-cause, cardiovascular, and cancer mortality in adults with CKD.
A meta-analysis of 22 studies found steatotic liver disease in about three-quarters of patients with sleep-disordered breathing.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Advertisement
Advertisement
Trending on AJMC
1
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
2
Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D
3
CMS Projects 16.5% Drop in 2027 Medicare Advantage Premiums
4
FDA Accepts Inhaled Treprostinil sNDA for IPF: 4 FAQs for Payers
5